, Nurittin Ardic2
1INVAMED Medical Innovation Institute, New York, NY, USA
2Med-International UK Health Agency Ltd., Leicestershire, UK
Copyright © 2025 The Korean Society for Preventive Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Point of view | Conventional | AI-powered |
|---|---|---|
| Diagnostic speed and accuracy | Time-consuming, usually subjective | Fast, consistent |
| Therapeutic approach | Experience or trial-and-error based, may not work every time | Data-driven, effective with greater precision |
| Personalization | Applicable in practice but limited | Highly personalized |
| Cost-effectiveness | Costly | Cost saving potential, especially in the long term |
| Scalability | Resource-intensive | Scalable and effective |
| Innovation speed | Gradual | Speeded up |
| AI applications | Definition | Examples |
|---|---|---|
| Diagnostic assistance | Determining diseases from genetic, social markers, etc. data | AI-powered predictive models integrated with genomic data or SDOH indicators |
| Predictive analysis | Prediction of health outcomes and risks of developing certain diseases based on patient data | Predicting COVID-19 outbreaks or risk scores for aortic aneurysm |
| Virtual healthcare assistants | AI-assisted tools that help patients and healthcare providers monitor, diagnose and communicate. | Telemedicine platforms and wearable sensors for real-time patient tracking. |
| Personalized patient management | Tailoring management for a specific disease based on genetics, or other patient data | Tailoring treatment recommendations based on SDOH |
| Drug and biomarker discovery | AI-assisted identification of new drug targets and biomarkers for disease therapy. | AI-powered drug discovery platforms that identify new therapeutic targets or predict drug responses based on patient-specific biomarkers. |
| Automatized workflow | Streamlining administrative, schedule and operational duties | Automating patient record management with the help of AI |
| Population-based personalization | Tailoring healthcare management to individuals from the general population who share a common characteristic such as age, health status or environment. | Predicting risk scores based on environment and life characteristics |
| Fundamental concern | Definition | Solution proposal |
|---|---|---|
| Data privacy, transparency, and liability | Extensive data analysis can lead to concerns about protecting sensitive patient data, transparency, and accountability | Processing sensitive information more securely by AI-driven encryption, developing transparent/explainable algorithms, and creating strict rules aimed at determining liability |
| Algorithmic bias | Algorithmic bias can lead to less accurate predictions or suboptimal recommendations for precision medicine | Training AI tools on diverse datasets and regularly auditing the models |
| Regulatory and policy gaps | Lack of effective frameworks for AI technology in healthcare, leading to its slower adoption | Establishing policies and guidelines tailored to specific necessity |
| Workforce, accessibility, cost | Limited resources and high initial costs to deploy AI solutions can lead to inefficient healthcare delivery; Genomic sequencing and personalized treatments can be costly | Establishing ongoing training, planning comprehensive and long-term investment, sharing the workload between private and public |
| Category | Pros | Cons |
|---|---|---|
| Diagnostics | AI helps detect diseases accurately and quickly by analysing large amounts of medical data | Implementation of effective AI application is hampered by the lack of large and well-annotated datasets, which represent diverse population |
| Personalized treatment | Allows for interventions based on customized medical history, genetics, and lifestyle | Patients may prefer human interaction and emotional support rather than AI-assisted interventions |
| Predictive analytic | Facilitates proactive healthcare by predicting disease trends and patient outcomes | If training data is not inclusive, algorithmic biases can cause existing inequalities to persist |
| Drug development | Identifies potential drug candidates and accelerates the research and development process | Over-reliance on AI systems can reduce professionals’ critical decision-making skills |
| Remote monitoring | AI-assisted devices provide real-time health monitoring and timely intervention | Legal and ethical challenges arise around data privacy, accountability, and equity |
| Equal access | Improve health care delivery in underserved areas | High costs and resource requirements may cause application challenges in low-resource environments |
AI, artificial intelligence; SDOH, social determinants of health; COVID-19, coronavirus disease 2019.